Skip to content

An Observational Study for the Evaluation of Circulating Tumor Cells Based on EpCAM Antibody Recognition by Microfluidic Chip for therapeutic Effect Evaluation of Gastric Cancer

An Observational Study for the Evaluation of Circulating Tumor Cells Based on EpCAM Antibody Recognition by Microfluidic Chip for therapeutic Effect Evaluation of Gastric Cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800017834
Enrollment
Unknown
Registered
2018-08-16
Start date
2018-11-01
Completion date
Unknown
Last updated
2018-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

Gold Standard:Histological test
Index test:antibody&#32
technology

Sponsors

Department of Oncology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. histologically confirmed gastric cancer. 2. the stage of gastric cancer was clearly defined by surgery or imaging. 3. Aged 18-80 years old. 4. baseline PS score was 0-1 points. 5. normal liver and kidney function and bone marrow reserve: The white blood cell is more than 3 x10^9/L; The absolute value of neutrophils (ANC) is greater than 1.5 x10^9/L; The platelet count is more than 100 x10^9/L; Hemoglobin (Hb) is more than 9g/dL; Total bilirubin is less than 1.5 x upper limit of normal value (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than 3 x ULN; Serum creatinine less than 1.5 x ULN; 6. the informed consent has been fully understood and signed voluntarily; 7. at least one measurable lesion in patients with advanced gastric cancer (RECIST 1.1); 8. the expected survival is more than 12 weeks.

Exclusion criteria

Exclusion criteria: 1. patients during pregnancy or lactation; 2. serious medical diseases beyond control; 3. second type of malignant tumor in the past 5 years.

Design outcomes

Primary

MeasureTime frame
Circulating cancer cell;SEN, SPE, ACC;

Countries

China

Contacts

Public ContactXiuying Xiao

Department of Oncology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University

xiaoxiuying2002@163.com+86 13564579313

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026